These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 11561568

  • 21. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J, Ariza H, Jardim JR, Caballero A, García-Calderón A, Amábile-Cuevas CF, Hernández-Oliva G, Vivar-Orozco R, MOX-CB Study Group.
    Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.
    Stein GE.
    Clin Ther; 1999 Nov; 21(11):1864-72. PubMed ID: 10890258
    [Abstract] [Full Text] [Related]

  • 24. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB.
    Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
    Loran OB, Pushkar' DIu, Rasner PI.
    Klin Med (Mosk); 2001 Dec; 79(12):35-8. PubMed ID: 11840809
    [Abstract] [Full Text] [Related]

  • 28. Once daily isepamicin treatment in complicated urinary tract infections.
    Lee SS, Liu YC, Wann SR, Lin WR, Tsai TH, Lin HH, Chen YS, Yen MY.
    J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Clinical evaluation of ofloxacin against complicated urinary tract infections].
    Nishio S, Yoshihara H.
    Hinyokika Kiyo; 1987 Sep; 33(9):1503-7. PubMed ID: 3481217
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice.
    Spencer RC, Cole TP.
    Br J Clin Pract; 1992 Aug; 46(1):30-3. PubMed ID: 1419551
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A, Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group.
    N Engl J Med; 2005 Sep 08; 353(10):988-98. PubMed ID: 16148284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.